From the Norton Children's and University of Louisville School of Medicine, Louisville, Kentucky.
Merck & Co., Inc., Rahway, New Jersey.
Pediatr Infect Dis J. 2022 Sep 1;41(9):775-781. doi: 10.1097/INF.0000000000003609. Epub 2022 Jun 24.
The recommended US infant immunization schedule includes doses of diphtheria, tetanus, acellular pertussis (DTaP), inactivated poliovirus (IPV), Haemophilus influenzae type b (Hib) and hepatitis B virus (HepB) during the first 6 months of life. Little information is available about the timing of associated, complementary monovalent vaccine administration in infants receiving DTaP-based pentavalent combination vaccines.
This was a retrospective cohort study of infants born between July 1, 2010, and June 30, 2018, in the US MarketScan commercial claims and encounters database. Descriptive statistics were used to assess vaccine administration patterns. Multivariate logistic regression was performed to explore factors associated with coadministration of DTaP-IPV/Hib and HepB.
Among infants who received DTaP-HepB-IPV (n = 129,885), 93.7% had claims for at least 2 Hib doses; most (91.5%-98.3%) of these doses were administered on the same day as DTaP-HepB-IPV doses. Among infants who received DTaP-IPV/Hib (n=214,172), 95.3% had claims for ≥2 doses of HepB. Although coverage was high, 59.2% received the second HepB dose on the same day as the first DTaP-IPV/Hib dose, and 44.6% received the third dose of HepB on the same day as the third DTaP-IPV/Hib dose. Differences in coadministration of the second and third HepB doses with DTaP-IPV/Hib were associated with the region of residence, provider type, health plan type and coadministration of pneumococcal conjugate vaccine and rotavirus vaccine.
Almost all infants received the appropriate, complementary monovalent vaccine series. However, this study found variability in the timing of HepB doses in relation to DTaP-IPV/Hib doses with many infants not completing the HepB series until 9 months of age.
美国推荐的婴儿免疫计划包括在生命的前 6 个月内接种白喉、破伤风、无细胞百日咳(DTaP)、灭活脊髓灰质炎(IPV)、流感嗜血杆菌 b 型(Hib)和乙型肝炎病毒(HepB)疫苗。关于接受基于 DTaP 的五联疫苗的婴儿同时接种相关、补充单价疫苗的时间安排,信息有限。
这是一项在美国 MarketScan 商业索赔和就诊数据库中对 2010 年 7 月 1 日至 2018 年 6 月 30 日期间出生的婴儿进行的回顾性队列研究。使用描述性统计数据评估疫苗接种模式。进行多变量逻辑回归以探讨与 DTaP-IPV/Hib 和 HepB 共同给药相关的因素。
在接受 DTaP-HepB-IPV(n=129885)的婴儿中,93.7%有至少 2 剂 Hib 的报告;这些剂量中的大多数(91.5%-98.3%)与 DTaP-HepB-IPV 剂量同一天给予。在接受 DTaP-IPV/Hib(n=214172)的婴儿中,95.3%有≥2 剂 HepB 的报告。尽管覆盖率很高,但 59.2%的婴儿在同一天接种第一剂 DTaP-IPV/Hib 后接种第二剂 HepB,44.6%的婴儿在同一天接种第三剂 DTaP-IPV/Hib 后接种第三剂 HepB。与 DTaP-IPV/Hib 共同给予第二和第三剂 HepB 剂量的差异与居住地、提供者类型、健康计划类型以及肺炎球菌结合疫苗和轮状病毒疫苗的共同给药有关。
几乎所有婴儿都接受了适当的、互补的单价疫苗系列。然而,本研究发现 HepB 剂量与 DTaP-IPV/Hib 剂量的时间安排存在差异,许多婴儿直到 9 个月大时才完成 HepB 系列接种。